RESONATE™-2 secondary endpoint: ORR with IMBRUVICA® vs chlorambucil1

Primary analysis: At median follow-up of 18.4 months, 82% ORR with IMBRUVICA® vs 35% ORR with chlorambucil (secondary endpoint)1,2

 

Overall response rate IMBRUVICA® vs chlorambucil